Průběh obhajoby diplomové práce: Diplomová práce na téma ''Zdravotnictví a jeho postaveni ve veřejném sekto '' byla ve
![PDF) Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy PDF) Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy](https://i1.rgstatic.net/publication/276900159_Subcutaneous_Bortezomib_in_Multiple_Myeloma_Patients_Induces_Similar_Therapeutic_Response_Rates_as_Intravenous_Application_But_It_Does_Not_Reduce_the_Incidence_of_Peripheral_Neuropathy/links/564c99ec08ae3374e5e05406/largepreview.png)
PDF) Subcutaneous Bortezomib in Multiple Myeloma Patients Induces Similar Therapeutic Response Rates as Intravenous Application But It Does Not Reduce the Incidence of Peripheral Neuropathy
Zápis z jednání Komise při Radě města Litoměřice Komise životního prostředí č. 06/2017 konané dne 25.09.2017 od 1
![PDF) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice PDF) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice](https://i1.rgstatic.net/publication/348533101_Survival_benefit_of_ixazomib_lenalidomide_and_dexamethasone_IRD_over_lenalidomide_and_dexamethasone_Rd_in_relapsed_and_refractory_multiple_myeloma_patients_in_routine_clinical_practice/links/6004198aa6fdccdcb85c4fe7/largepreview.png)